Aurinia Pharmaceuticals (AUPH) reported third-quarter 2026 total revenue of $83.7 million, up 14% from $73.5 million a year earlier. Net income was $31.7 million, compared with $31.6 million in the prior-year quarter, while diluted earnings per share remained $0.23.
The company raised its 2026 total revenue guidance to $325 million to $330 million from $315 million to $325 million. Aurinia also narrowed net product sales guidance to $310 million to $315 million.
- LUPKYNIS net product sales were $79.4 million in the third quarter, up 12% year over year.
- Nine-month total revenue was $244.6 million, up 19%, and nine-month net income was $103.5 million, up 35%.
- Cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026.
- Aurinia initiated the PRESERVE Phase 4 study evaluating LUPKYNIS combinations in lupus nephritis.
$AUPH Insider Trading Activity
$AUPH insiders have traded $AUPH stock on the open market 7 times in the past 6 months. Of those trades, 5 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $AUPH stock by insiders over the last 6 months:
- KEVIN TANG (Chief Executive Officer) has made 5 purchases buying 814,606 shares for an estimated $12,455,227 and 0 sales.
- STEPHEN P. ROBERTSON (Chief Legal Officer) has made 0 purchases and 2 sales selling 32,914 shares for an estimated $546,372.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AUPH Hedge Fund Activity
We have seen 149 institutional investors add shares of $AUPH stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC added 4,185,893 shares (+292.0%) to their portfolio in Q2 2026, for an estimated $71,034,604
- TANG CAPITAL MANAGEMENT LLC added 1,714,606 shares (+15.1%) to their portfolio in Q2 2026, for an estimated $29,096,863
- MAN GROUP PLC removed 768,783 shares (-90.2%) from their portfolio in Q2 2026, for an estimated $13,046,247
- TREXQUANT INVESTMENT LP removed 523,950 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $8,891,431
- QUBE RESEARCH & TECHNOLOGIES LTD removed 450,661 shares (-48.4%) from their portfolio in Q2 2026, for an estimated $7,647,717
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 445,990 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,568,450
- JANE STREET GROUP, LLC removed 415,506 shares (-91.9%) from their portfolio in Q2 2026, for an estimated $7,051,136
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
